awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38804812-595A0777-8B46-418C-8978-EEC3504714AE
Q38804812-595A0777-8B46-418C-8978-EEC3504714AE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38804812-595A0777-8B46-418C-8978-EEC3504714AE
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-
P2860
Q38804812-595A0777-8B46-418C-8978-EEC3504714AE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38804812-595A0777-8B46-418C-8978-EEC3504714AE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d9af0bac3785455d494764229e62c3cbe4a63e2d
P2860
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.